Brief: Aquestive Therapeutics Exceeds Top End Of Guidance Range For Preliminary Unaudited Full Year 2019 Total Revenues And Provides Initial Full Year 2020 Guidance

Allon Therapeutics

10/01/2020 11:37

Jan 10 (Reuters) - Aquestive Therapeutics Inc  AQST.O :
    * AQUESTIVE THERAPEUTICS EXCEEDS TOP END OF GUIDANCE RANGE
FOR
PRELIMINARY UNAUDITED FULL YEAR 2019 TOTAL REVENUES AND PROVIDES
INITIAL FULL YEAR 2020 GUIDANCE
    * SEES FY 2019 REVENUE ABOUT $52 MILLION
    * SEES Q4 2019 REVENUE ABOUT $16 MILLION
    * EXPECTS PRELIMINARY UNAUDITED CASH AND CASH EQUIVALENTS AS
OF
DECEMBER 31, 2019 OF APPROXIMATELY $49 MILLION
    * AQUESTIVE THERAPEUTICS -SEES FULL YEAR 2020 TOTAL REVENUES
OF
ABOUT $35 MILLION TO $45 MILLION
    * AQUESTIVE THERAPEUTICS -SEES FY 2020 NON-GAAP ADJUSTED
EBITDA
LOSS OF ABOUT $65 MILLION TO $70 MILLION
    * FY2019 REVENUE VIEW $46.4 MILLION -- REFINITIV IBES DATA
    * Q4 REVENUE VIEW $10.2 MILLION -- REFINITIV IBES DATA

Source text for Eikon:  ID:nGNX9gkKnC 
Further company coverage:  AQST.O 

 ((Reuters.Briefs@thomsonreuters.com;))